dermatologyadvisor8d
Long-Term Lebrikizumab in AD Is Effective Despite Inadequate Short-Term Response
Long-term lebrikizumab was effective for atopic dermatitis treatment in patients who did not have adequate response to short-term treatment.
Healio9d
‘Don’t give up’: Long-term lebrikizumab for AD may benefit initial nonresponders
Long-term treatment with lebrikizumab may be beneficial for patients with atopic dermatitis that were not initially ...
pharmaphorum12d
Almirall/Lilly lebrikizumab offers potential long-term management of atopic dermatitis
Lebrikizumab, a monoclonal antibody that inhibits an interleukin named IL-13, is especially promising in treatment of this disease. Having been in development by Almirall and Eli Lilly and Company ...
Pharmabiz3d
Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis
Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...
pharmaphorum5y
Almirall takes option on Dermira's eczema drug lebrikizumab
Spain’s Almirall has taken an option granting rights to develop and market Dermira’s eczema drug lebrikizumab in Europe, in a bid to take on Sanofi/Regeneron's recently approved Dupixent.